



Study supporting the monitoring of the availability of medical devices on the EU market

Survey results of the 18th NB survey (MDR/IVDR)
with data status 31 October 2025
(small and medium dataset)

25 March 2026

Disclaimer

- This document was produced in the frame of the SC 2021 P3 03 under the DG SANTE Framework contract (FWC SANTE/2021/OP/0002) for evaluation, impact assessment, monitoring and other related services in relation to health and food policies.
- The information and views set out in this document are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. Neither the Commission/Executive Agency nor any person acting on the Commission's/Executive Agency's behalf may be held responsible for the use which may be made of the information contained therein.
- This presentation includes data and knowledge available at the time of the publication. The study-related [dashboard](#) contains the latest information und updates (e.g. further insights, retrospective corrections reported by stakeholders). Data discrepancies between this presentation and the regularly updated dashboard are therefore possible.

Acknowledgements

The study team would like to sincerely thank the following institutions and people for the support in the 18th NB survey:

- All **52 notified bodies** designated under MDR and/or IVDR that participated in the survey (100% response rate);
- The Directorate General for Health and Food Safety at the European Commission (**DG SANTE**) and the European Health and Digital Executive Agency (**HaDEA**);
- Members of the **MDCG TF on certification capacity monitoring**.

Content

About

1. About the study, survey and datasets

MD

2. Survey results for medical devices

IVD

3. Survey results for in vitro diagnostic medical devices

Please cite as: Austrian National Public Health Institute, Areté, Civic Consulting (2026). PowerPoint presentation containing a study overview and survey results of the 18th NB survey for the 'Study supporting the monitoring of availability of medical devices on the EU market'. Austrian National Public Health Institute (Gesundheit Österreich GmbH / GÖG). Commissioned by the European Commission within the EU4Health Programme (under specific contract No 2021 P3 03 with the European Health and Digital Executive Agency, implementing framework contract No SANTE/2021/OP/0002).

List of abbreviations (1)

Abbreviation	Meaning
AIMDD	Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices
CE	Conformité Européenne
DG SANTE	Directorate-General for Health and Food Safety
EC	European Commission
EU	European Union
EURLs	EU reference laboratories
FTE	Full Time Equivalent
FWC	Framework contract
GÖG	Gesundheit Österreich GmbH / Austrian National Public Health Institute
HaDEA	European Health and Digital Executive Agency
IVDs	In-vitro diagnostic medical device(s)
IVDD	Directive 98/79/EC of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices
IVDR	Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 (In Vitro Diagnostic Medical Device Regulation)
LD	Large dataset

List of abbreviations (2)


Abbreviation	Meaning
MD	Medium dataset
MDCG	Medical Device Coordination Group
MDs	Medical device(s)
MDD	Council Directive 93/42/EEC of 14 June 1993 concerning medical devices
MDR	Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 (Medical Device Regulation)
MFs	Manufacturer(s)
NBs	Notified body / bodies
QMS	Quality Management System
SC	Special contract
SD	Small dataset
SMCS	Single Market Compliance Space
SMEs	Small and medium-sized enterprise(s)
TF	Task Force


1. About the study, survey and datasets


- Study supporting the monitoring of availability of medical devices on the EU market
- Preliminary notes
- NB survey overview
- Dashboard
- Survey timeline
- Response rate

Study supporting the monitoring of availability of medical devices on the EU market

- **Commissioned by:** The European Commission’s Directorate-General for Health and Food Safety (DG SANTE) via the European Health and Digital Executive Agency (HaDEA)
- **Aim:** To support monitoring and analyzing the availability of medical devices on the EU market in the context of the implementation of medical devices and in vitro diagnostic medical devices Regulations from the perspectives of key stakeholders
- **Duration:** 2 December 2022 – 1 June 2026 (42 months*)
* Study amendment from 2 December 2025 – 1 June 2026
- **Study team** (contact: medical.devices@goeg.at):

 **Gesundheit Österreich GmbH** Austrian National Public Health Institute (Gesundheit Österreich GmbH / GÖG) → project lead

 **Areté** The Agri-food Intelligence Company

 **CIVIC CONSULTING** Civic Consulting

Supported by experts from the medical devices sector

Preliminary notes

- **Data content:**

- The following slides show the results of the **18th NB survey conducted at the beginning of November 2025** with **requested data** from notified bodies designated under MDR and/or IVDR **until 31 October 2025**.
- These survey results are also compared with previous survey data (see data sources).

- **Data sources:**

- Data collected between April 2023 and November 2025 by the study team
- Data collected between February 2021 and October 2022 by the European Commission

- **Datasets:**

- This presentation contains the results of the small and medium datasets collected in November 2025.
 - Ⓢ The **small dataset** is a small set of questions asked to notified bodies **every two months**.
Note: From April to July 2023, it was asked monthly.
 - Ⓜ The **medium dataset** is a set of questions asked to notified bodies **every four months** concerning the activities they have been performing since their designation.
 - Ⓛ The **large dataset** contains additional data asked to notified bodies **once a year**.

NB survey overview

NB survey	Survey period (survey launch – survey closure)	Requested dataset*	Requested data	Response rate
1 st NB survey	03/04/2023 - 05/05/2023	SD1 + MD1	from designation up to 31/03/2023	39 out of 39 NBs (100%)
2 nd NB survey	12/05/2023 - 05/06/2023	SD2	from designation up to 30/04/2023	27 out of 39 NBs (~70%)
3 rd NB survey	05/06/2023 - 19/06/2023	SD3	from designation up to 31/05/2023	22 out of 39 NBs (~56%)
4 th NB survey	03/07/2023 - 28/07/2023	SD4 + MD2	from designation up to 30/06/2023	39 out of 39 NBs (100%)
5 th NB survey	01/09/2023 - 06/10/2023	SD5	from designation up to 31/08/2023	40 out of 40 NBs (100%)
6 th NB survey	03/11/2023 - 22/12/2023	SD6 + MD3 + LD1	from designation up to 31/10/2023	41 out of 41 NBs (100%)
7 th NB survey	08/01/2024 - 05/02/2024	SD7	from designation up to 31/12/2023	45 out of 45 NBs (100%)
8 th NB survey	04/03/2024 - 20/03/2024	SD8 + MD4	from designation up to 29/02/2024	45 out of 45 NBs (100%)
9 th NB survey	02/05/2024 - 21/06/2024	SD9	from designation up to 30/04/2024	48 out of 48 NBs (100%)
10 th NB survey	01/07/2024 - 06/08/2024	SD10 + MD5	from designation up to 30/06/2024	50 out of 50 NBs (100%)
11 th NB survey	02/09/2024 - 17/10/2024	SD11	from designation up to 31/08/2024	50 out of 50 NBs (100%)
12 th NB survey	06/11/2024 – 20/12/2024	SD12 + MD6 + LD2 + TE1*	from designation up to 31/10/2024	51 out of 51 NBs (100%)
13 th NB survey	21/01/2025 – 27/02/2025	SD13 + TE2**	from designation up to 31/12/2024	51 out of 51 NBs (100%)
14 th NB survey	03/03/2025 – 08/04/2025	SD14 + MD7	from designation up to 28/02/2025	51 out of 51 NBs (100%)
15 th NB survey	05/05/2025 – 23/05/2025	SD15	from designation up to 30/04/2025	51 out of 51 NBs (100%)
16 th NB survey	01/07/2025 – 02/09/2025	SD16 + MD8 + LD3	from designation up to 30/06/2025	51 out of 51 NBs (100%)
17 th NB survey	01/10/2025 – 04/11/2025	SD17 + TR	from designation up to 30/08/2025	51 out of 51 NBs (100%)
18 th NB survey	14/11/2025 – 15/12/2025	SD18 + MD9	from designation up to 31/10/2025	52 out of 52 NBs (100%)

18th NB survey results are presented in this PowerPoint presentation

Note: SD = small dataset, MD = medium dataset, LD = large dataset, TE = Targeted Evaluation, TR = Targeted Revision
 * About the targeted evaluation: Evaluations conducted by the European Commission assess how well a specific policy intervention has performed (or is performing) and whether it is still relevant and justified. Evaluations are a key component of the lifecycle of any policy intervention. For the MDR and IVDR, the Commission has a legal obligation to conduct an evaluation of the Regulations by May 2027 (Article 121 MDR/Article 111 IVDR). The Commission has decided to launch a targeted evaluation of the Regulations in 2024. The 12th and 13th NB survey (conducted in the framework of the 'Study supporting the monitoring of the availability of medical devices on the EU market') were used to ask NBs questions that are relevant for the Targeted Evaluation.

Dashboard

- NB survey results are presented in the study-related dashboard
- Available at: [Study supporting the monitoring of availability of medical devices on the EU market - European Commission \(europa.eu\)](https://ec.europa.eu/health/medical_devices_dashboard/)
- [Instructions for use for the dashboard](#)

Monitoring the Availability of Medical Devices and In Vitro Diagnostic Medical Devices in the EU

Home | About | Process Indicators | MDR Outcomes | IVDR Outcomes | Glossary/Links | Contact/Help

Welcome to the dashboard monitoring the availability of medical devices and in vitro diagnostic medical devices in the European Union

Medical devices (MDs) and in vitro diagnostic medical devices (IVDs) are essential for a working healthcare system and play a crucial role in the prevention, diagnosis, monitoring, prediction, prognosis and treatment of acute and chronic illnesses and diseases as well as rehabilitation. However, they require a strong regulatory framework to ensure safety and optimal performance.

Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), which replace the previous regulatory framework in the European Union (EU), aim to improve the safety, performance and effectiveness of medical devices as well as, strengthen transparency and provide information for patients while enhancing vigilance and market surveillance. In order to ensure a smooth transition from the previous regulatory framework, it is essential to regularly appraise the situation on the ground and gather concrete data on the activities currently performed by relevant stakeholders.

A study was commissioned by the European Commission (via its European Health and Digital Executive Agency / HaDEA) from *Gesundheit Österreich GmbH (Austrian National Public Health Institute)*, *Civic Consulting* and *Areté* with the support of four regulatory experts to monitor the availability of medical devices on the EU market. Starting in December 2022 and lasting 36 months, the study aims to monitor and analyse the availability of medical devices on the EU market in the context of the implementation of Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices. As part of the project, this dashboard was established.

The dashboard presents an overview of the data gathered from different stakeholders monitoring the availability of MDs and IVDRs in the EU. In addition, comparable data from previous surveys of notified bodies conducted by the European Commission have been integrated in the dashboard and can be found on the MDR/IVDR Outcomes overview pages.

Latest update: 28.11.2024

Please contact: medical.devices@ec.europa.eu

MD Availability Dashboard 2.2

Monitoring the Availability of Medical Devices and In Vitro Diagnostic Medical Devices in the EU

Home | About | Process Indicators | MDR Outcomes | IVDR Outcomes | Glossary/Links | Contact/Help

Overview | Applications & Certificates | Temporal & Qualitative | Entities & Structure | Products & Codes | Transition & Projections

Select stakeholder: Notified Bodies (NB)

Select figure: Overview indicators (MDR)

Overview indicators (MDR)

Number of files

Compare: Total valid MDD/AIMDD certificates: 25.034 (04/22)

2023-03 2023-04 2023-05 2023-06 2023-08 2023-10 2023-12 2024-02 2024-04 2024-06 2024-08

Applications total
Written agreements signed
QMS certificates issued
QMS certificates issued (first time only)
Product certificates issued
Product certificates issued (first time only)
Applications refused

Please hover over the dots in the figure to see detailed numbers.

How to interpret: Detailed information on displayed figure

This figure displays an overview of the (main) indicators on applications and certifications for medical devices under the MDR for the surveys performed. Notified bodies reported on how many written agreements they have signed, how many applications from economic operators have been refused, how many QMS and product certificates they have issued as well as how many certification applications have been received in total. Note that these data are collected within the small dataset (every two months) and are displayed and updated accordingly. From October 2023: Change in methodology of counting by a few NBs.

Select all, one or several of these indicators by clicking on the black buttons. For a selected indicator its definition and detailed information are shown in the infobox below.

Select all | Applications total | Written agreements signed | QMS certificates issued | QMS certificates issued (first time only) | Product certificates issued | Product certificates issued (first time only) | Applications refused

How to interpret: Detailed information on displayed indicator

Response rate per survey in %

100
50


Applications refused: Specific reasons: The NB shall have documented procedures to review applications, addressing (a) the completeness of those applications with respect to the requirements of the relevant conformity assessment procedure, (b) the verification of the qualification of products covered by those applications as devices and their respective classifications, (c) whether the conformity assessment procedures chosen by the applicant are applicable to the device in question under this Regulation, (d) the ability of the NB to assess the application based on its designation, and (e) the availability of sufficient and appropriate resources.

MD Availability Dashboard 2.2

Timeline for the 18th NB survey

(conducted in November 2025 with requested data from designation up to 31/10/2025)

52 notified bodies
designated under MDR
and/or IVDR
(data status: 31 October 2025)



Note: Out of 52 notified bodies, 33 NBs are designated under the MDR only, 18 NBs are designated under both the MDR and IVDR, and 1 NB is designated under the IVDR only.


Response rate for the 18th NB survey

(conducted in November 2025 with requested data from designation up to 31/10/2025)

52 out of 52 notified bodies replies received (100% response rate)


Note: Out of 52 notified bodies, 33 NBs are designated under the MDR only, 18 NBs are designated under both the MDR and IVDR, and 1 NB is designated under the IVDR only.

MD



100% response rate

IVD



100% response rate

2. Survey results for medical devices

Note:


- Thousands separators are represented as dots or blank space (not comma) in the graphs.
- Datasets:
 - ③ The **small dataset** is a small set of questions asked to notified bodies **every two months**.
Note: From April to July 2023, it was asked monthly.
 - ④ The **medium dataset** is a set of questions asked to notified bodies **every four months** concerning the activities they have been performing since their designation.
 - ⑤ The **large dataset** contains additional data asked to notified bodies **once a year**.

Small dataset ©

The **small dataset** is a small set of questions asked to notified bodies **every two months**.

From April to July 2023, it was asked monthly.


MDR applications filed and refused, written agreements signed




Notes:

- **Designated NBs for MDR: 51**
- **Applications lodged:** This number includes **all applications lodged (syn. filed) so far** according to MDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in the [Single Market Compliance Space](#) to the date of the survey up to 31/10/2025), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing MDR certificates. Pre-application activities are not included.
- **Written agreements signed:** This refers to the number of written agreements (contracts) between a NB and a manufacturer signed by both parties.

MDR number of QMS / product certificates issued



Note QMS Certificates: This relates to Annex IX Chapter I or Annex XI Part A according to MDR.




Note PRODUCT Certificates: This relates to Annex IX Chapter II, Annex X or Annex XI Part B according to MDR.

Survey comparison – March 2023 to October 2025

Number of total certification applications lodged incl. no. of applications with issued certificates

Number of written agreements signed




- S#18: from designation up to 31/10/2025
- S#17: from designation up to 30/08/2025
- S#16: from designation up to 30/06/2025
- S#15: from designation up to 30/04/2025
- S#14: from designation up to 28/02/2025
- S#13: from designation up to 31/12/2024
- S#12: from designation up to 31/10/2024
- S#11: from designation up to 31/08/2024
- S#10: from designation up to 30/06/2024
- S#9: from designation up to 30/04/2024
- S#8: from designation up to 29/02/2024
- S#7: from designation up to 31/12/2023
- S#6: from designation up to 31/10/2023
- S#5: from designation up to 30/08/2023
- S#4: from designation up to 30/06/2023
- S#3: from designation up to 31/05/2023
- S#2: from designation up to 30/04/2023
- S#1: from designation up to 31/03/2023

18

Notes:

- S = Survey; # = number
- Survey #18: 51 designated NBs for MDR
- Surveys #2 and #3 did not reach 100% response rate (#2: ~70%; #3: 56%). In this case, for the NBs that did not respond, data from previous surveys were included in the total for each indicator.
- Change in methodology of counting applications by one NB in survey #13


Survey comparison – March 2023 to October 2025



Notes:

- S = Survey; # = number
- Survey **#18**: 51 designated NBs for MDR
- Surveys **#2** and **#3** did not reach 100% response rate (#2: ~70%; #3: 56%). In this case, for the NBs that did not respond, data from previous surveys were included in the total for each indicator.
- Change in methodology of counting refused applications compared to previous surveys by NBs in survey #11, #12, #13 and #18.

Survey comparison – March 2023 to October 2025



S = Survey; # = number

Notes:

- Survey #18: 51 designated NBs for MDR
- Surveys #2 and #3 did not reach 100% response rate (#2: ~70%; #3: 56%). In this case, for the NBs that did not respond, data from previous surveys were included in the total for each indicator.
- Increase from survey #1 to #3; in survey #4, the questionnaire was redesigned, and the question on "total number of certificates issued" (in addition to "first time only") was included in the small dataset. The redesign of the questionnaire helped the NBs to better assess the number of first-time only certificates. Therefore, the numbers of the previous surveys might be an overestimation.
- Change in methodology of counting by a few NBs compared to previous surveys in survey #4 and #5.


Medium dataset

The **medium dataset** is a set of questions asked to notified bodies **every four months** concerning the activities they have been performing since their designation.

MDR applications filed and certificates issued (sum of Annexes)



October 2025
MDR Applications:
 Total number of applications filed by Annex [Ⓜ]: 33.175*
MDR Certificates:
 Total number of certificates by Annex [Ⓜ]: 17.549




Notes: Designated NBs for MDR: 51

- * The data shown comes from the medium data set [Ⓜ] – except for 3 NBs where the total number of applications filed was derived from the small data set [Ⓢ], as they are not able to provide complete data per Annex.
- Δ (Delta) = Difference in MDR Applications / MDR Certificates from one survey to the next one
- **Applications filed:** This number includes **all applications filed (syn. lodged) so far** according to MDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in the [Single Market Compliance Space](#) to the date of the survey up to 31/10/2025), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing MDR certificates. Pre-application activities are not included. One application can correspond to more than one certificate.
- **Certificates issued:** This number includes **certificates issued so far** (from designation up 31/10/2025) under the MDR.
- The dotted line shows the polynomial trend line (grade 2).

MDR applications by annex – survey comparison

Applications survey comparison


October 2025 MDR Applications: 33.292*



Notes:

- Designated NBs for MDR: 51; NBs that included Annex XVI products in the numbers provided: 28
- * The data shown comes from the medium data set [Ⓜ] – except for 3 NBs where the total number of applications filed was derived from the small data set [Ⓢ], as they are not able to provide complete data per Annex.
- ** Change in methodology of counting by a few NBs, leading to decreases.
- **Applications lodged by annex:** This number includes **all applications lodged (syn. filed) by annex** according to MDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in the [Single Market Compliance Space](#) to the date of the survey up to 31/10/2025), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing MDR certificates. Pre-application activities are not included. One application can correspond to more than one certificate.

MDR certificates by annex - survey comparison



- Notes:**
- Designated NBs for MDR: 51; NBs that included Annex XVI products in the numbers provided: 28
 - * The data shown comes from the medium data set
 - ** Change in methodology of counting by one NB leading to a decrease
 - **Certificates issued by annex:** This number includes certificates issued so far (from designation up to 31/10/2025) under the MDR by annex.

MDR applications and certificates by type (QMS vs Product) – survey comparison



October 2025



MDR Applications:

Total number of applications filed by Annex : 33.175*

MDR Certificates:

Total number of certificates by Annex : 17.549

* The data shown comes from the medium data set (applications and certificates by Annex: 3 NBs could not provide the complete application information by Annex; hence the total number of applications is higher - see number in the small data set).



Note QMS Applications and Certificates: This relates to Annex IX Chapter I or Annex XI Part A according to MDR.

Note PRODUCT Applications and Certificates: This relates to Annex IX Chapter II, Annex X or Annex XI Part B according to MDR.

Total number of applications lodged for changes received for already MDR issued certificates: 7.367

Note: This number is included in the total number of applications.

Specific additional procedures according to Annex IX (II)


October 2025

MDR Applications:

Total number of applications filed [by Annex](#) [Ⓜ]: 33.292*

MDR Certificates:

Total number of certificates [by Annex](#) [Ⓜ]: 17.581



Notes:


* The data shown comes from the medium data set [Ⓜ] – except for 3 NBs where the total number of applications filed was derived from the small data set [Ⓢ] since they could not provide the data per Annex.

Average timeframe to written agreement signed

Average timeframe between application lodged and written agreement signed:



MDR applications - reasons for refusal



Total number of MDR applications:

October 2022: 8120
March 2023: 11.418
June 2023: 13.177
October 2023: 17.846*
February 2024: 20.424*
June 2024: 26.185*
October 2024: 28.069*
February 2025: 28.489*
June 2025: 32.974*
October 2025: 33.292*

* The total number comes from the medium data set (M) – except for a few NBs where the total number of applications filed was derived from the small data set (S) since they could not provide complete data per Annex.


Number of application refusals**:

October 2022: 232
March 2023: 269
June 2023: 328
October 2023: 367
February 2024: 454
June 2024: 576
October 2024: 562
February 2025: 650
June 2025: 727
October 2025: 918

Notes:

- ** Applications can have multiple reasons for refusal; the total number shown is derived from the small data set and differ from the figures in the medium data set indicated on the graph on this slide.
- October 2025: some stated “other” reasons in October 2025: “cancellation/withdrawal by the customer”, “requirements not met”; “concerns about violation of Article 7 and/or prejudice; “client stopped communication”, “unresolved non-conformities”, “outside the scope of insurance”, “language difference”, “voluntary renounce”, “costs”

Completeness of submissions



Number of notified bodies which report that > 50% of submissions are considered complete:
14 out of 51 NBs designated under MDR in October 2025


Incomplete submissions remain high*

*Estimated percentage of submissions which were deemed satisfactory in terms of documentation provided (before undertaking the review of its content) without requesting for any additional information

Time to reach a new certificate (QMS vs QMS+PRODUCT)

October 2025
 MDR Applications: 33.292*
 MDR Certificates: 17.581

* The total number comes from the medium data set
 M – except for 3 NBs where the total number of applications filed was derived from the small data set
 ©, as they are not able to provide complete data per Annex



MDR QMS certificates

- 59% of NBs: 13-18 months to issue a new QMS certificate
- 33% of NBs: 6-12 months

MDR QMS+PRODUCT certificates: longer time


- 53% of NBs: 13-18 months
- 28% of NBs: 19-24 months

Notes:

- This indicator shows the time to reach issuance of a new EC certificate (from written agreement signed to issuance) under MDR
- QMS+PRODUCT: Data of 36 NBs designated under MDR; 15 NBs indicated that no QMS+PRODUCT certificate was issued yet
- QMS: Data of 46 NBs designated under MDR; 5 NBs indicated that no QMS certificate was issued yet

Questions on Annex XVI products

(products with no intended medical purpose that fall under the scope of the MDR)



Notes:

14th NB survey: 24 out of 50 NBs entered "0" for all questions relating to Annex XVI products.


16th NB survey: 22 out of 50 NBs entered "0" for all questions relating to Annex XVI products

18th NB survey: 23 out of 50 NBs entered "0" for all questions relating to Annex XVI products.


Certificates issued for products without an intended medical purpose* and for dual purpose devices**

* Products **without an intended medical purpose** that are listed in Annex XVI to the MDR are covered by that Regulation from 22 June 2023, which is the date of application of Annex XVI common specifications set out in Commission Implementing Regulation (EU) 2022/2346.

** **Dual purpose devices**: products having both a medical and a non-medical intended purpose



Notes: Data of 10 NBs; 40 out of 50 NBs entered "0" for all groups




Notes: Data of 13 NBs; 38 out of 51 NBs entered "0" for all groups

LIST OF GROUPS OF PRODUCTS WITHOUT AN INTENDED MEDICAL PURPOSE REFERRED TO IN ARTICLE 1(2) MDR

1. Contact lenses or other items intended to be introduced into or onto the eye.
2. Products intended to be totally or partially introduced into the human body through surgically invasive means for the purpose of modifying the anatomy or fixation of body parts with the exception of tattooing products and piercings.
3. Substances, combinations of substances, or items intended to be used for facial or other dermal or mucous membrane filling by subcutaneous, submucous or intradermal injection or other introduction, excluding those for tattooing.
4. Equipment intended to be used to reduce, remove or destroy adipose tissue, such as equipment for liposuction, lipolysis or lipoplasty.
5. High intensity electromagnetic radiation (e.g. infra-red, visible light and ultra-violet) emitting equipment intended for use on the human body, including coherent and non-coherent sources, monochromatic and broad spectrum, such as lasers and intense pulsed light equipment, for skin resurfacing, tattoo or hair removal or other skin treatment.
6. Equipment intended for brain stimulation that apply electrical currents or magnetic or electromagnetic fields that penetrate the cranium to modify neuronal activity in the brain.

Single-use devices and their reprocessing (Article 17 MDR)

- Yes, certificate issued
- Not applicable (not in the designation scope of the NB)
- No certificates issued yet (although in the designation scope of the NB)




Data of 51 NBs designated under MDR

One NB indicated issuance of certificates:


- **5 certificates** issued in accordance with Art. 17(2)
- **No certificates** issued in accordance with Art. 17(5)

Article 117 MDR opinions* - requests received and opinions issued



Notes 16th NB survey:

- Total number of requests for Article 117 MDR opinions for initial market authorization submissions received: data of 22 NBs
- Total number of requests for Article 117 MDR opinions for changes received: data of 6 NBs



Notes 18th NB survey:

- Total number of requests for Article 117 MDR opinions for initial market authorization submissions received: data of 25 NBs
- Total number of requests for Article 117 MDR opinions for changes received: data of 6 NBs

* **Article 117 MDR:** Where, in accordance with the second subparagraph of Article 1(8) or the second subparagraph of Article 1(9) of Regulation (EU) 2017/745 of the European Parliament and of the Council, a product is governed by this Directive, the marketing authorisation dossier shall include, where available, the results of the assessment of the conformity of the device part with the relevant general safety and performance requirements set out in Annex I to that Regulation contained in the manufacturer's EU declaration of conformity or the relevant certificate issued by a notified body allowing the manufacturer to affix a CE marking to the medical device.

34


If the dossier does not include the results of the conformity assessment referred to in the first subparagraph and where for the conformity assessment of the device, if used separately, the involvement of a notified body is required in accordance with Regulation (EU) 2017/745, the authority shall require the applicant to provide an opinion on the conformity of the device part with the relevant general safety and performance requirements set out in Annex I to that Regulation issued by a notified body designated in accordance with that Regulation for the type of device in question.

3. Survey results for in vitro diagnostic medical devices

Note:

- Thousands separators are represented as dots or blank space (not comma) in the graphs.
- Datasets:
 - Ⓢ The **small dataset** is a small set of questions asked to notified bodies **every two months**.
Note: From April to July 2023, it was asked monthly.
 - Ⓜ The **medium dataset** is a set of questions asked to notified bodies **every four months** concerning the activities they have been performing since their designation.
 - Ⓛ The **large dataset** contains additional data asked to notified bodies **once a year**.


IVDR applications filed and refused, written agreements signed




Notes:

- **Designated NBs for IVDR:** 19
- **Applications lodged:** This number includes **all applications lodged (syn. filed) so far** according to IVDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in the [Single Market Compliance Space](#) to the date of the survey up to 31/10/2025), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing MDR certificates. Pre-application activities are not included.
- **Written agreements signed:** This refers to the number of written agreements (contracts) between a NB and a manufacturer signed by both parties.

IVDR Number of QMS / product certificates issued




Note QMS Certificates: This relates to Annex IX Chapter I or Annex XI according to IVDR.



Note PRODUCT Certificates: This relates to Annex IX Chapter II, Annex X or Annex XI according to IVDR.

Survey comparison – March 2023 to October 2025




S = Survey; # = number

Notes:

- Designated NBs for IVDR: S#1 to S#5: 10; S#6 to S#11: 12; S#12 to S#13: 13; S#14: 14; S#15: 16, S#16: 17, S#17: 18, S#18: 19
- Surveys #2 and #3 did not reach 100% response rate (S#2: ~70%; S#3: 56%). In this case, for the NBs that did not respond, data from previous surveys were included in the total for each indicator.

Survey comparison – March 2023 to October 2025




S = Survey; # = number

Notes:

- Designated NBs for IVDR: S#1 to S#5: 10; S#6 to S#11: 12; S#12 to S#13: 13; S#14: 14; S#15: 16, S#16:16, S#17: 18, S#18: 19 (1 NB reported 95 refused applications)
- Surveys #2 and #3 did not reach 100% response rate (S#2: ~70%; S#3: 56%). In this case, for the NBs that did not respond, data from previous surveys were included in the total for each indicator.
- Change in methodology of counting refused applications compared to previous surveys by NBs in survey #12.

Survey comparison – March 2023 to October 2025



S = Survey; # = number

Notes:


- Designated NBs for IVDR: S#1 to S#5: 10; S#6 to S#11: 12; S#12 to S#13: 13; S#14: 14; S#15: 16, S#16: 17, S#17: 18, S#18: 19
- Surveys #2 and #3 did not reach 100% response rate (S#2: ~70%; S#3: 56%). In this case, for the NBs that did not respond, data from previous surveys were included in the total for each indicator.

Medium dataset

The **medium dataset** is a set of questions asked to notified bodies **every four months** concerning the activities they have been performing since their designation.

IVDR applications lodged and certificates issued

October 2025
IVDR Applications: 3.634
IVDR Certificates: 2.194



Notes: Designated NBs for IVDR in October 2025: 19

- Δ (Delta) = Difference in IVDR Applications / IVDR Certificates from one survey to the next one
- **Applications lodged:** This number includes **all applications lodged (syn. filed) so far** according to IVDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in the [Single Market Compliance Space](#) to the date of the survey up to 31/10/2025), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing IVDR certificates. Pre-application activities are not included. One application can correspond to more than one certificate.
- **Certificates issued:** This number includes **certificates issued so far** (from designation up to 31/10/2025) under the IVDR.
- The dotted line shows the polynomial trend line (grade 2).

IVDR applications and certificates by annex


IVD



October 2025

IVDR Applications: 3.634



IVDR Certificates: 2.194



Notes:

- **Applications lodged by annex:** This number includes all applications lodged (syn. filed) by annex according to IVDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in NANDO to the date of the survey up to 31/10/2025), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing MDR certificates. Pre-application activities are not included. One application can correspond to more than one certificate.
- **Certificates issued by annex:** This number includes certificates issued so far (from designation up to 31/10/2025) under the IVDR by annex.
- **Class D devices are included** in the total number of applications/certificates.


IVDR applications and certificates by annex – surveys comparison



Notes:

- **Applications lodged by annex:** This number includes **all applications lodged (syn. filed) by annex** according to IVDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in the [Single Market Compliance Space](#) to the date of the survey up to 31/10/2025), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing IVDR certificates. Pre-application activities are not included. One application can correspond to more than one certificate.
- **Certificates issued by annex:** This number includes **certificates issued so far** (from designation up to 31/10/2025) under the IVDR by annex.

Class D devices applications and certificates



October 2025
IVDR Applications: 3.634
IVDR Certificates: 2.194

October 2025:
Total number of Class D devices Applications: 1.097
Total number of Class D devices Certificates: 630



Notes:

- **Applications lodged by annex:** This number includes all applications lodged (syn. filed) by annex according to IVDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in the [Single Market Compliance Space](#) to the date of the survey up to 31/10/2025), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing IVDR certificates. Pre-application activities are not included. One application can correspond to more than one certificate.
- **Certificates issued by annex:** This number includes certificates issued so far (from designation up to 31/10/2025) under the IVDR by annex.
- Data for Annex XI has changed compared to previous surveys because of a change in methodology of counting by NBs.



Class D IVDs applications and certificates development

October 2025:
 Total number of Class D devices applications: 1.097
 Total number of Class D devices certificates: 630



Note:
Applications lodged by annex: This number includes all applications lodged (syn. filed) by annex according to IVDR Annex VII section 4.3 (from the day when the designation became valid, i.e. one day after publication in NANDO to the date of the survey up to **31/10/2025**), i.e.: applications with issued certificates, applications without decisions on the outcome of the conformity assessment activities, applications that were eventually refused or withdrawn by the manufacturer (including transferred applications), applications lodged for changes of existing MDR certificates. Pre-application activities are not included. One application can correspond to more than one certificate.

Note:
Certificates issued by annex: This number includes certificates issued so far (from designation up to **31/10/2025**) under the IVDR by annex.


Applications and certificates requiring consultation for companion diagnostics (CDx)*

IVD



October 2025:
 Class D devices applications: 1.097
 Class D devices certificates: 630


October 2025
 IVDR Applications: 3.634
 IVDR Certificates: 2.194



* According to [Article 2 \(7\) IVDR](#), a companion diagnostic means a device which is essential for the safe and effective use of a corresponding medicinal product to:
 (a) identify, before and/or during treatment, patients who are most likely to benefit from the corresponding medicinal product; or
 (b) identify, before and/or during treatment, patients likely to be at increased risk of serious adverse reactions as a result of treatment with the corresponding medicinal product.
 ** Change in methodology of counting by one NB from the 14th NB Survey onwards.
 18th NB survey: data of 2 NBs


Collaboration with EU reference laboratories (EURLs) on Class D devices (1)

Has a **Class D application** been lodged within the scope of EURL oversight?



■ Yes ■ No

Has a **Class D certificate** been issued within the scope of EURL oversight?



■ Yes ■ No

* Number of NBs of which at least one **Class D application** has been lodged from 1 October 2024 within the scope of EURL oversight

Data of 19 NBs designated under IVDR

Collaboration with EU reference laboratories (EURLs) on Class D devices (2)

IVD



Class D applications

	Hepatitis and retrovirus	Respiratory viruses	Bacterial pathogens	Herpes virus	TOTAL
Total number of class D devices (covered by an application lodged [from 01/10/2024 up to 31/10/2025]) that fall in the categories of currently designated EURLs	111	6	42	9	168
Number of devices covered by a signed master services agreement with an EURL for performance verification (EURL task in IVDR Article 100(2)(a) [as of 31/10/2025])	446	10	24	16	496
Number of devices that is or was covered by a signed statement of work with an EURL for performance verification (EURL task in IVDR Article 100(2)(a)) [as of 31/10/2025]	22	0	0	0	22
Number of devices for which performance verification by EURLs has been scheduled or completed [as of 31/10/2025]	50	0	0	0	50

Data of 9 NBs designated under IVDR

Collaboration with EU reference laboratories (EURLs) on Class D devices (3)

Class D certificates

	Hepatitis and retrovirus	Respiratory viruses	Bacterial pathogens	Herpes virus	TOTAL
Total number of class D devices (covered by issued certificates [as of 31/10/2025]) that fall in the categories of currently designated EURLs	488	46	38	47	619
Number of devices covered by a signed master services agreement with an EURL for batch testing (EURL task in IVDR Article 100(2)(b) [as of 31/10/2025]	519	21	30	19	589
Number of devices covered by a signed statement of work with an EURL for batch testing (EURL task in IVDR Article 100(2)(b)) [as of 31/10/2025]	428	8	24	16	476
Number of devices for which batch testing by EURLs is in practical operation [as of 31/10/2025]*	268	2	9	0	279
Number of batches tested by an EURL from the date on which the corresponding EURLs became available for tasks in conformity assessment (1 October 2024) [as of 31/10/2025]* Note: cumulative sum across devices in category	475	28	1	0	504
Number of batches tested by alternative means (e.g. by an independent testing laboratory) from the date on which the corresponding EURLs became available for tasks in conformity assessment (1 October 2024) [as of 31/10/2025]**	292	0	0	2	294


Data of 4 NBs designated under IVDR

* Note: this refers to the overall process being in place in practice, and not whether a batch is being tested at the time of reporting.

**This question was asked in the 18th NB survey for the first time.


Comparison of EURLs results of the 14th, 16th and 18th NB survey

Class D applications



- 14th NB survey: data of 4 NBs designated under IVDR
- 16th NB survey: data of 8 NBs designated under IVDR
- 18th NB survey: data of 9 NBs designated under IVDR

Class D certificates




- 14th NB survey: data of 3 NBs designated under IVDR
- 16th NB survey: data of 3 NBs designated under IVDR
- 18th NB survey: data of 4 NBs designated under IVDR

* This question was not asked in this survey round. n.a. = not available;

** Differing questions in the 16th and 18th NB surveys:

- 16th NB survey: Number of batches tested [as of 30/06/2025]
- 18th NB survey: Number of batches tested by an EURL from the date on which the corresponding EURLs became available for tasks in conformity assessment (1 October 2024) [as of 31/10/2025]

IVDR applications - reason for refusal



October 2025
IVDR Applications: 3.634
IVDR Certificates: 2.194


Total number of IVDR application refusals*:

- October 2022: 2
- March 2023: 49
- June 2023: 16
- October 2023: 6
- February 2024: 7
- June 2024: 7
- October 2024: 7
- February 2025: 12
- June 2025: 14
- October 2025: 111

Notes:

- * Applications can have multiple reasons for refusal; the total number shown is derived from the small data set and differ from the figures in the medium data set indicated on the graph on this slide."
- October 2025: "Other" reasons: "not able to complete conformity assessment process", "client stopped communication".

Completeness of submissions




Number of notified bodies which report that > 50% of submissions are considered complete:
7 out of 19 NBs in October 2025

Submissions remain incomplete*

* Estimated percentage of submissions which were deemed satisfactory in terms of documentation provided (before undertaking the review of its content) without requesting for any additional information


Average timeframe to written agreement signed

Average timeframe between application lodged and written agreement signed



Time to reach a new certificate (QMS vs QMS+PRODUCT)

October 2025
IVDR Applications: 3.634
IVDR Certificates: 2.194



IVDR QMS certificates

- 55% of NBs: 6-12 months to issue a new QMS certificate
- 36% of NBs: 13-18 months

IVDR QMS+PRODUCT certificates: longer time

- 75% of NBs: 13-18 months
- 8% of NBs: 19-24 months

Notes:

- This indicator shows the time to reach issuance of a new EC certificate (from written agreement signed to issuance) under IVDR.
- QMS+PRODUCT: Data of 12 NBs designated under IVDR
- QMS: Data of 11 NBs designated under IVDR

Thank you

Contact for questions: medical.devices@goeg.at

Austrian National Public Health Institute/ Gesundheit Österreich (GÖG)



© European Union 2026

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.